Please provide your email address to receive an email when new articles are posted on . Teprotumumab reduces proptosis by 2 mm or more for most adults with long-standing thyroid eye disease and low ...

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced new pooled efficacy data from the Phase 2 and 3 clinical trials of TEPEZZA™ (teprotumumab-trbw) showing that the ...

Please provide your email address to receive an email when new articles are posted on . A 41-year-old woman was referred to the neuro-ophthalmology service at the New England Eye Center for left-sided ...

Findings from THRIVE showed treatment with veligrotug led to statistically significant improvements in the signs and symptoms of TED. Topline data were announced from a phase 3 study evaluating ...

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in a Phase 3 clinical trial (OPTIC-J) in Japan evaluating teprotumumab for the ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in a Phase 4 clinical trial evaluating the efficacy and safety of TEPEZZA for ...

A 14-year-old African-American female presented to the emergency room with a 2-day history of her left eye "sticking out." According to the patient, she awoke 2 days prior and noticed that her left ...

A 60-year-old white woman complains of progressive double vision in the left eye that began 8 months ago. She also notes tearing and discharge from the eye and complains of increased bulging of the ...

Researchers from the Schepens Eye Research Institute of Massachusetts Eye and Ear have identified new underlying mechanisms of proptosis, or bulging of the eyes, in patients with acute thyroid eye ...

Powerful anti-tumor response associated with reduction in proptosis (eye-bulging) and reduced ocular pain Heavily pre-treated patient had failed 7 prior regimens including antibody-drug conjugate ...

-- Teprotumumab is marketed under the brand name TEPEZZA® in the United States-- The primary efficacy endpoint is proptosis response rate at Week 24, measured by the percentage of participants with at ...